Overview

Why Invest

Profitable specialty pharmaceutical company with a diversified portfolio

Cipher’s lean operating structure and collaborative approach to commercialization and development enable rapid and efficient scaling while maximizing our profitability.

Solid dermatology platform

Established presence across the Americas

Strong balance sheet

History of positive operating cash flow

Robust pipeline

Proven leadership team

Download Investor Presentation

Latest News

E-mail Alerts

Sep 5, 2023

Cipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian Dollars

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company"), is announcing its intention to commence a substantial issuer bid (the "Offer" or "SIB") pursuant to which the Company will offer...

Aug 10, 2023

Cipher Pharmaceuticals Releases Q2 2023 Results, Announces Launch of Epuris in Mexico

(All figures are presented in U.S. dollars) Strong growth capital available with $36.3 million in cash and cash equivalents Net income increased by 32% year-over-year to $5.7 million EPS increased...

Jul 28, 2023

Cipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference Call

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the second quarter of 2023 on Thursday, August 10, 2023. The...

More News >

Ticker

TSXCPH

Q2 2023 Results

Press Release